1-(4-nitrophenyl)-3-(trifluoromethyl)piperidine | 500015-05-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(4-nitrophenyl)-3-(trifluoromethyl)piperidine
• CAS: 500015-05-4
• 化学式: C₁₂H₁₃F₃N₂O₂
• 分子量: 274.243
• InChiKey: GOMXWUJOKDHSBV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  49.1
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-(4-nitrophenyl)-3-(trifluoromethyl)piperidine 在 palladium 10% on activated carbon 作用下， 以 甲醇 为溶剂， 25.0 ℃ 、303.99 kPa 条件下， 以84.21 %的产率得到4-[3-(trifluoromethyl)piperidin-1-yl]aniline
  参考文献：
  名称：

  [EN] NOVEL PHENYLAMINOPYRIMIDINE COMPOUND HAVING INHIBITORY ACTIVITY AGAINST LRRK2 AND USE THEREOF
  [FR] NOUVEAU COMPOSÉ DE PHÉNYLAMINOPYRIMIDINE AYANT UNE ACTIVITÉ INHIBITRICE CONTRE LRRK2 ET SON UTILISATION
  [KO] LRRK2에 대해 저해 활성을 갖는 신규한 페닐아미노피리미딘 화합물 및 이의 용도

  摘要：

  本发明提供了一种化学式为1的嘧啶化合物，以及包含该化合物的用于预防或治疗由LRRK2介导或与之相关的疾病（例如帕金森病）的药物组合物，以及使用该组合物治疗和预防疾病或疾病的方法。根据本发明，嘧啶化合物具有优异的LRRK2抑制活性，可有效用于预防或治疗与LRRK2相关的疾病（例如帕金森病）。

  公开号：

  WO2022203466A1

文献信息

• TRICYCLIC INHIBITORS OF KINASES
  申请人：Tong Yunsong

  公开号：US20120220572A1

  公开（公告）日：2012-08-30

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein X, Y, Z, R 3 and R 4 are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.

  本发明涉及式(I)的化合物或药用可接受的盐，其中X、Y、Z、R3和R4在描述中有定义。本发明还涉及含有上述化合物的组合物，用于抑制wee-1等激酶，并治疗癌症等疾病的方法。
• Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals
  申请人：——

  公开号：US20030212070A1

  公开（公告）日：2003-11-13

  The present invention relates to aminoalkyl-substituted aromatic bicyclic compounds of formula I, 1 which are valuable pharmaceutically active compounds that are suitable, for example, for the treatment of obesity, type II diabetes, arteriosclerosis, high blood pressure, paresthesia, depression, anxiety, anxiety neuroses, schizophrenia, disorders associated with the circadian rhythm, and drug abuse, as well as normalizing lipid metabolism.

  本发明涉及公式I的氨基烷基取代芳香双环化合物，这些化合物是有价值的药用活性化合物，例如适用于治疗肥胖症、2型糖尿病、动脉硬化、高血压、感觉异常、抑郁症、焦虑症、焦虑神经症、精神分裂症、与昼夜节律相关的疾病以及药物滥用，同时还能正常化脂质代谢。
• US8710065B2
  申请人：——

  公开号：US8710065B2

  公开（公告）日：2014-04-29
• [EN] TRICYCLIC INHIBITORS OF KINASES<br/>[FR] INHIBITEURS TRICYCLIQUES DE KINASES
  申请人：ABBOTT LAB

  公开号：WO2012161812A1

  公开（公告）日：2012-11-29

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, ( l ) wherein X, Y, Z, R3 and R4 are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.
• [EN] NOVEL PHENYLAMINOPYRIMIDINE COMPOUND HAVING INHIBITORY ACTIVITY AGAINST LRRK2 AND USE THEREOF<br/>[FR] NOUVEAU COMPOSÉ DE PHÉNYLAMINOPYRIMIDINE AYANT UNE ACTIVITÉ INHIBITRICE CONTRE LRRK2 ET SON UTILISATION<br/>[KO] LRRK2에 대해 저해 활성을 갖는 신규한 페닐아미노피리미딘 화합물 및 이의 용도
  申请人：STANDIGM INC

  公开号：WO2022203466A1

  公开（公告）日：2022-09-29

  본 발명은 화학식 1의 피리미딘 화합물, 이를 포함하는 LRRK2에 의해 매개되거나 이와 관련된 질병(예컨대, 파킨슨병)의 예방 또는 치료용 약학적 조성물, 및 이를 이용한 질병 또는 질환의 치료 및 예방 방법을 제공한다. 본 발명에 따른 피리미딘 화합물은 LRRK2 저해 활성이 우수하여 LRRK2와 관련된 질병(예컨대, 파킨슨병)의 예방 또는 치료에 효과적으로 사용될 수 있다.

  本发明提供了一种化学式为1的嘧啶化合物，以及包含该化合物的用于预防或治疗由LRRK2介导或与之相关的疾病（例如帕金森病）的药物组合物，以及使用该组合物治疗和预防疾病或疾病的方法。根据本发明，嘧啶化合物具有优异的LRRK2抑制活性，可有效用于预防或治疗与LRRK2相关的疾病（例如帕金森病）。